Vitamin D and multiple sclerosis

The Lancet Neurology

Volumn 9, Issue 6, 2010, Pages 599-612

  Ascherio, Alberto ^a,b   Munger, Kassandra L ^a   Simon, K Claire ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; CALCITRIOL; CALCIUM; COLECALCIFEROL; HLA DR ANTIGEN; VITAMIN D;

ALLERGIC ENCEPHALOMYELITIS; CLINICAL TRIAL; DISEASE COURSE; DRUG MEGADOSE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; INCIDENCE; LATITUDE; MULTIPLE SCLEROSIS; NONHUMAN; OBESITY; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; RECALL BIAS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SKIN COLOR; SUN EXPOSURE; ULTRAVIOLET RADIATION; VITAMIN BLOOD LEVEL; VITAMIN D METABOLISM; VITAMIN INTAKE;

ANIMALS; DISEASE PROGRESSION; HUMANS; MULTIPLE SCLEROSIS; RISK FACTORS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 77952314178     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(10)70086-7     Document Type: Review

References (196)

1. Ascherio A., and Munger K.L. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol 61 (2007) 288-299
2. Ascherio A., and Munger K.L. Environmental risk factors for multiple sclerosis. Part II: noninfectious factors. Ann Neurol 61 (2007) 504-513
3. Holick M.F. Vitamin D deficiency. N Engl J Med 357 (2007) 266-281
4. Goldberg P. Multiple sclerosis: vitamin D and calcium as environmental determinants of prevalence (a viewpoint). Part 1: sunlight, dietary factors and epidemiology. Intern J Environ Stud 6 (1974) 19-27
5. Hayes C.E., Cantorna M.T., and Deluca H.F. Vitamin D and multiple sclerosis. Proc Soc Exp Biol Med 216 (1997) 21-27
6. Holick M.F. Vitamin D: a millenium perspective. J Cell Biochem 88 (2003) 296-307
7. Holick M.F. Environmental factors that influence the cutaneous production of vitamin D. Am J Clin Nutr 61 suppl (1995) 638S-645S
8. Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations and safety. Am J Clin Nutr 69 (1999) 842-856
9. Zerwekh J.E. Blood biomarkers of vitamin D status. Am J Clin Nutr 87 suppl (2008) 1087S-1091S
10. Matsuoka L.Y., Ide L., Wortsman J., MacLaughlin J.A., and Holick M.F. Sunscreens suppress cutaneous vitamin D3 synthesis. J Clin Endocrinol Metab 64 (1987) 1165-1168
11. Matsuoka L.Y., Wortsman J., Haddad J.G., and Hollis B.W. In vivo threshold for cutaneous synthesis of vitamin D3. J Lab Clin Med 114 (1989) 301-305
12. Yetley E.A. Assessing the vitamin D status of the US population. Am J Clin Nutr 88 suppl (2008) 558S-564S
13. Holick M.F. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 80 suppl (2004) 1678S-1688S
14. Engelsen O., Brustad M., Aksnes L., and Lund E. Daily duration of vitamin D synthesis in human skin with relation to latitude, total ozone, altitude, ground cover, aerosols and cloud thickness. Photochem Photobiol 81 (2005) 1287-1290
15. Norman A.W. Vitamin D receptor (VDR): new assignments for an already busy receptor. Endocrinology 147 (2006) 5542-5548
16. Norman A.W. From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health. Am J Clin Nutr 88 (2008) 491S-499S
17. Mawer E.B., Lumb G.A., and Stanbury S.W. Long biological half-life of vitamin D3 and its polar metabolites in human serum. Nature 222 (1969) 482-483
18. Smith J.E., and Goodman D.S. The turnover and transport of vitamin D and of a polar metabolite with the properties of 25-hydroxycholecalciferol in human plasma. J Clin Invest 50 (1971) 2159-2167
19. Holick M.F., Biancuzzo R.M., Chen T.C., et al. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab 93 (2008) 677-681
20. Bischoff-Ferrari H.A., Giovannucci E., Willett W.C., Dietrich T., and Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 84 (2006) 18-28
21. Bischoff-Ferrari H. Vitamin D: what is an adequate vitamin D level and how much supplementation is necessary?. Best Pract Res Clin Rheumatol 23 (2009) 789-795
22. Looker A.C., Pfeiffer C.M., Lacher D.A., Schleicher R.L., Picciano M.F., and Yetley E.A. Serum 25-hydroxyvitamin D status of the US population: 1988-1994 compared with 2000-2004. Am J Clin Nutr 88 (2008) 1519-1527
23. Hypponen E., and Power C. Hypovitaminosis D in British adults at age 45 y: nationwide cohort study of dietary and lifestyle predictors. Am J Clin Nutr 85 (2007) 860-868
24. Haddad J.G., and Chyu K.J. Competitive protein-binding radioassay for 25-hydroxycholecalciferol. J Clin Endocrinol Metab 33 (1971) 992-995
25. Better O.S., Shabtai M., Kedar S., Melamud A., Berenheim J., and Chaimovitz C. Increased incidence of nephrolithiasis in lifeguards in Israel. In: Massry S.G., Ritz E., and Jahreis G. (Eds). Phosphate and minerals in health and disease (1980), Plenum Press, New York 467-472
26. Dawson-Hughes B., Heaney R.P., Holick M.F., Lips P., Meunier P.J., and Vieth R. Estimates of optimal vitamin D status. Osteoporos Int 16 (2005) 713-716
27. Deluca H.F., and Cantorna M.T. Vitamin D: its role and uses in immunology. FASEB J 15 (2001) 2579-2585
28. Holick M.F., and Chen T.C. Vitamin D deficiency: a worldwide problem with health consequences. Am J Clin Nutr 87 suppl (2008) 1080S-1086S
29. McCann J.C., and Ames B.N. Is there convincing biological or behavioral evidence linking vitamin D deficiency to brain dysfunction?. FASEB J 22 (2008) 982-1001
30. Lemire J.M., and Archer D.C. 1,25-Dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest 87 (1991) 1103-1107
31. 3. J Neuroimmunol 61 (1995) 151-160
32. Cantorna M.T., Hayes C.E., and DeLuca H.F. 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci USA 93 (1996) 7861-7864
33. Spach K.M., Nashold F.E., Dittel B.N., and Hayes C.E. IL-10 signaling is essential for 1,25-dihydroxyvitamin D3-mediated inhibition of experimental autoimmune encephalomyelitis. J Immunol 177 (2006) 6030-6037
34. Nataf S., Garcion E., Darcy F., Chabannes D., Muller J.Y., and Brachet P. 1,25 Dihydroxyvitamin D3 exerts regional effects in the central nervous system during experimental allergic encephalomyelitis. J Neuropathol Exp Neurol 55 (1996) 904-914
35. Cantorna M.T., Hayes C.E., and DeLuca H.F. 1,25-Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. J Nutr 128 (1998) 68-72
36. Nashold F.E., Miller D.J., and Hayes C.E. 1,25-Dihydroxyvitamin D3 treatment decreases macrophage accumulation in the CNS of mice with experimental autoimmune encephalomyelitis. J Neuroimmunol 103 (2000) 171-179
37. 3 to suppress experimental autoimmune encephalomyelitis in mice. Arch Biochem Biophys 408 (2002) 200-204
38. Nashold F.E., Hoag K.A., Goverman J., and Hayes C.E. Rag-1-dependent cells are necessary for 1,25-dihydroxyvitamin D3 prevention of experimental autoimmune encephalomyelitis. J Neuroimmunol 119 (2001) 16-29
39. Hayes C.E., Nashold F.E., Spach K.M., and Pedersen L.B. The immunological functions of the vitamin D endocrine system. Cell Mol Biol 49 (2003) 277-300
40. Becklund B.R., Hansen Jr. D.W., and Deluca H.F. Enhancement of 1,25-dihydroxyvitamin D3-mediated suppression of experimental autoimmune encephalomyelitis by calcitonin. Proc Natl Acad Sci USA 106 (2009) 5276-5281
41. Spach K.M., and Hayes C.E. Vitamin D3 confers protection from autoimmune encephalomyelitis only in female mice. J Immunol 175 (2005) 4119-4126
42. Nashold F.E., Spach K.M., Spanier J.A., and Hayes C.E. Estrogen controls vitamin D3-mediated resistance to experimental autoimmune encephalomyelitis by controlling vitamin D3 metabolism and receptor expression. J Immunol 183 (2009) 3672-3681
43. Hauser S.L., Weiner H.L., Che M., Shapiro M.E., Gilles F., and Letvin N.L. Prevention of experimental allergic encephalomyelitis (EAE) in the SJL/J mouse by whole body ultraviolet irradiation. J Immunol 132 (1984) 1276-1281
44. Schneider H.A. Suppression of experimental allergic encephalomyelitis by microwaves from flourescent lamps. In: Alter M., and Kurtzke J.F. (Eds). The epidemiology of multiple sclerosis (1968), CC Thomas, Springfield
45. Lucas R.M., and Ponsonby A.L. Considering the potential benefits as well as adverse effects of sun exposure: can all the potential benefits be provided by oral vitamin D supplementation?. Prog Biophys Mol Biol 92 (2006) 140-149
46. Mahon B.D., Gordon S.A., Cruz J., Cosman F., and Cantorna M.T. Cytokine profile in patients with multiple sclerosis following vitamin D supplementation. J Neuroimmunol 134 (2003) 128-132
47. Jorde R., Sneve M., Torjesen P.A., Figenschau Y., Goransson L.G., and Omdal R. No effect of supplementation with cholecalciferol on cytokines and markers of inflammation in overweight and obese subjects. Cytokine 50 (2010) 175-180
48. Royal III W., Mia Y., Li H., and Naunton K. Peripheral blood regulatory T cell measurements correlate with serum vitamin D levels in patients with multiple sclerosis. J Neuroimmunol 213 (2009) 135-141
49. Smolders J., Thewissen M., Peelen E., et al. Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis. PLoS One 4 (2009) e6635
50. Correale J., Ysrraelit M.C., and Gaitan M.I. Immunomodulatory effects of vitamin D in multiple sclerosis. Brain 132 (2009) 1146-1160
51. Viglietta V., Baecher-Allan C., Weiner H.L., and Hafler D.A. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 199 (2004) 971-979
52. Chen T.C., Chimeh F., Lu Z., et al. Factors that influence the cutaneous synthesis and dietary sources of vitamin D. Arch Biochem Biophys 460 (2007) 213-217
53. Kurtzke J.F., Beebe G.W., and Norman J.E. Epidemiology of multiple sclerosis in U.S. veterans: 1. Race, sex, and geographic distribution. Neurology 29 (1979) 1228-1235
54. Harris S.S. Vitamin D and African Americans. J Nutr 136 (2006) 1126-1129
55. van der Mei I.A., Ponsonby A.L., Dwyer T., et al. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol 254 (2007) 581-590
56. Glass D., Lens M., Swaminathan R., Spector T.D., and Bataille V. Pigmentation and vitamin D metabolism in caucasians: low vitamin D serum levels in fair skin types in the UK. PLoS One 4 (2009) e6477
57. Handel A.E., Giovannoni G., Ebers G.C., and Ramagopalan S.V. Environmental factors and their timing in adult-onset multiple sclerosis. Nat Rev Neurol 6 (2010) 156-166
58. Gale C.R., and Martyn C.N. Migrant studies in multiple sclerosis. Prog Neurobiol 47 (1995) 425-448
59. Binkley N., Krueger D., Cowgill C.S., et al. Assay variation confounds the diagnosis of hypovitaminosis D: a call for standardization. J Clin Endocrinol Metab 89 (2004) 3152-3157
60. Brot C., Jorgensen N.R., and Sorensen O.H. The influence of smoking on vitamin D status and calcium metabolism. Eur J Clin Nutr 53 (1999) 920-926
61. Caire-Juvera G., Ritenbaugh C., Wactawski-Wende J., Snetselaar L.G., and Chen Z. Vitamin A and retinol intakes and the risk of fractures among participants of the Women's Health Initiative Observational Study. Am J Clin Nutr 89 (2009) 323-330
62. Carlberg C., Bendik I., Wyss A., et al. Two nuclear signalling pathways for vitamin D. Nature 361 (1993) 657-660
63. Greenland S. Tests for interaction in epidemiologic studies: a review and a study of power. Stat Med 2 (1983) 243-251
64. Acheson E.D., Bachrach C.A., and Wright F.M. Some comments on the relationship of the distribution of multiple sclerosis to latitude, solar radiation, and other variables. Acta Psychiatr Scand 147 suppl (1960) 132-147
65. Miller D.H., Hammond S.R., McLeod J.G., Purdie G., and Skegg D.C. Multiple sclerosis in Australia and New Zealand: are the determinants genetic or environmental?. J Neurol Neurosurg Psychiatry 53 (1990) 903-905
66. Hammond S.R., McLeod J.G., Millingen K.S., et al. The epidemiology of multiple sclerosis in three Australian cities: Perth, Newcastle and Hobart. Brain 111 (1988) 1-25
67. Chapuy M.C., Preziosi P., Maamer M., et al. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int 7 (1997) 439-443
68. Vukusic S., Van Bockstael V., Gosselin S., and Confavreux C. Regional variations of multiple sclerosis prevalence in French farmers. J Neurol Neurosurg Psychiatry 78 (2007) 707-709
69. van der Mei I.A., Ponsonby A.L., Engelsen O., et al. The high prevalence of vitamin D insufficiency across Australian populations is only partly explained by season and latitude. Environ Health Perspect 115 (2007) 1132-1139
70. Swank R.L., Lerstad O., Strøm A., and Backer J. Multiple sclerosis in rural Norway. Its geographic and occupational incidence in relation to nutrition. N Engl J Med 246 (1952) 721-728
71. Westlund K. Distribution and mortality time trend of multiple sclerosis and some other diseases in Norway. Acta Neurol Scand 46 (1970) 455-483
72. Kurtzke J.F., Beebe G.W., and Norman J.E. Epidemiology of multiple sclerosis in US veterans: III. Migration and the risk of MS. Neurology 35 (1985) 672-678
73. Pugliatti M., Rosati G., Carton H., et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol 13 (2006) 700-722
74. Alonso A., and Hernan M.A. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 71 (2008) 129-135
75. Hernán M.A., Olek M.J., and Ascherio A. Geographic variation of MS incidence in two prospective studies of US women. Neurology 53 (1999) 1711-1718
76. Wallin M.T., Page W.F., and Kurtzke J.F. Multiple sclerosis in US veterans of the Vietnam era and later military service: race, sex, and geography. Ann Neurol 55 (2004) 65-71
77. Mayr W.T., Pittock S.J., McClelland R.L., et al. Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985-2000. Neurology 61 (2003) 1373-1377
78. Fleming J., and Fabry Z. The hygiene hypothesis and multiple sclerosis. Ann Neurol 61 (2007) 85-89
79. Hallee T.J., Evans A.S., Niederman J.C., Brooks C.M., and Voegtly J.H. Infectious mononucleosis at the United States Military Academy. A prospective study of a single class over four years. Yale J Biol Med 3 (1974) 182-195
80. Thacker E.L., Mirzaei F., and Ascherio A. Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann Neurol 59 (2006) 499-503
81. Harrison H.E. A tribute to the first lady of public health (Martha M. Eliot). V. The disappearance of rickets. Am J Public Health Nations Health 56 (1966) 734-737
82. Ginde A.A., Liu M.C., and Camargo Jr. C.A. Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. Arch Intern Med 169 (2009) 626-632
83. Looker A.C., Lacher D.A., Pfeiffer C.M., Schleicher R.L., Picciano M.F., and Yetley E.A. Data advisory with regard to NHANES serum 25-hydroxyvitamin D data. Am J Clin Nutr 90 (2009) 695
84. Munger K.L., Levin L.I., Hollis B.W., Howard N.S., and Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 296 (2006) 2832-2838
85. Ozgocmen S., Bulut S., Ilhan N., Gulkesen A., Ardicoglu O., and Ozkan Y. Vitamin D deficiency and reduced bone mineral density in multiple sclerosis: effect of ambulatory status and functional capacity. J Bone Miner Metab 23 (2005) 309-313
86. Kragt J., van Amerongen B., Killestein J., et al. Higher levels of 25-hydroxyvitamin D are associated with a lower incidence of multiple sclerosis only in women. Mult Scler 15 (2009) 9-15
87. Soilu-Hanninen M., Airas L., Mononen I., Heikkila A., Viljanen M., and Hanninen A. 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Mult Scler 11 (2005) 266-271
88. Ahn J., Stolzenberg-Solomon R., Simon K., et al. Genome-wide association study of circulating vitamin D levels. Hum Mol Genet (2010) 10.1093/hmg/ddq155 published online April 23.
89. Sowers M.R., Wallace R.B., Hollis B.W., and Lemke J.H. Parameters related to 25-OH-D levels in a population-based study of women. Am J Clin Nutr 43 (1986) 621-628
90. Rock C.L., Thornquist M.D., Kristal A.R., et al. Demographic, dietary and lifestyle factors differentially explain variability in serum carotenoids and fat-soluble vitamins: baseline results from the sentinel site of the Olestra Post-Marketing Surveillance Study. J Nutr 129 (1999) 855-864
91. Scragg R., Holdaway I., Jackson R., and Lim T. Plasma 25-hydroxyvitamin D3 and its relation to physical activity and other heart disease risk factors in the general population. Ann Epidemiol 2 (1992) 697-703
92. Scragg R., Holdaway I., Singh V., Metcalf P., Baker J., and Dryson E. Serum 25-hydroxyvitamin D3 is related to physical activity and ethnicity but not obesity in a multicultural workforce. Aust N Z J Med 25 (1995) 218-223
93. Feskanich D., Willett W.C., and Colditz G.A. Calcium, vitamin D, milk consumption, and hip fractures: a prospective study among postmenopausal women. Am J Clin Nutr 77 (2003) 504-511
94. Munger K.L., Zhang S.M., O'Reilly E., et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 62 (2004) 60-65
95. Kampman M.T., Wilsgaard T., and Mellgren S.I. Outdoor activities and diet in childhood and adolescence relate to MS risk above the Arctic Circle. J Neurol 254 (2007) 471-477
96. van der Mei I., Ponsonby A.L., Dwyer T., et al. Past exposure to sun, skin phenotype and risk of multiple sclerosis: a case-control study. BMJ 327 (2003) 316-321
97. Ghadirian P., Jain M., Ducic S., Shatenstein B., and Morisset R. Nutritional factors in the aetiology of multiple sclerosis: a case-control study in Montreal, Canada. Int J Epidemiol 27 (1998) 845-852
98. Willett W.C. Nutritional epidemiology. 2nd edn. (1998), Oxford University Press, New York
99. Sahota H., Barnett H., Lesosky M., Raboud J.M., Vieth R., and Knight J.A. Association of vitamin D related information from a telephone interview with 25-hydroxyvitamin D. Cancer Epidemiol Biomarkers Prev 17 (2008) 232-238
100. van der Mei I.A., Blizzard L., Ponsonby A.L., and Dwyer T. Validity and reliability of adult recall of past sun exposure in a case-control study of multiple sclerosis. Cancer Epidemiol Biomarkers Prev 15 (2006) 1538-1544
101. Antonovsky A., Leibowitz U., Smith H.A., et al. Epidemiologic study of multiple sclerosis in Israel. Arch Neurol 13 (1965) 183-193
102. Cendrowski W., Wender M., Dominik W., Flejsierowicz Z., Owsianowski M., and Popiel M. Epidemiological study of multiple sclerosis in Western Poland. Eur Neurol 2 (1969) 90-108
103. Islam T., Gauderman W.J., Cozen W., and Mack T.M. Childhood sun exposure influences risk of multiple sclerosis in monozygotic twins. Neurology 69 (2007) 381-388
104. Freedman D.M., Dosemeci M., and Alavanja M.C. Mortality from multiple sclerosis and exposure to residential and occupational solar radiation: a case-control study based on death certificates. Occup Environ Med 57 (2000) 418-421
105. Westberg M., Feychting M., Jonsson F., Nise G., and Gustavsson P. Occupational exposure to UV light and mortality from multiple sclerosis. Am J Ind Med 52 (2009) 353-357
106. Simmons R.D., Ponsonby A.-L., van der Mei I., and Sheridan P. What affects your MS? Responses to an anonymous, internet-based epidemiological survey. Mult Scler 10 (2004) 202-221
107. Leiter U., and Garbe C. Epidemiology of melanoma and nonmelanoma skin cancer-the role of sunlight. In: Reichrath J. (Ed). Sunlight, vitamin D and skin cancer (2008), Springer, New York 89-103
108. Goldacre M.J., Seagroatt V., Yeates D., and Acheson E.D. Skin cancer in people with multiple sclerosis: a record linkage study. J Epidemiol Community Health 58 (2004) 142-144
109. Midgard R., Glattre E., Gronning M., Riise T., Edland A., and Nyland H. Multiple sclerosis and cancer in Norway. A retrospective cohort study. Acta Neurol Scand 93 (1996) 411-415
110. Nielsen N.M., Rostgaard K., Rasmussen S., et al. Cancer risk among patients with multiple sclerosis: a population-based register study. Int J Cancer 118 (2006) 979-984
111. Lebrun C., Debouverie M., Vermersch P., et al. Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis. Mult Scler 14 (2008) 399-405
112. Bahmanyar S., Montgomery S.M., Hillert J., Ekbom A., and Olsson T. Cancer risk among patients with multiple sclerosis and their parents. Neurology 72 (2009) 1170-1177
113. Willer C.J., Dyment D.A., Sadovnick A.D., Rothwell P.M., Murray T.J., and Ebers G.C. Timing of birth and risk of multiple sclerosis: population based study. BMJ 330 (2005) 120
114. Bell N.H., Epstein S., Greene A., Shary J., Oexmann M.J., and Shaw S. Evidence for alteration of the vitamin D-endocrine system in obese subjects. J Clin Invest 76 (1985) 370-373
115. Wortsman J., Matsuoka L.Y., Chen T.C., Lu Z., and Holick M.F. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 72 (2000) 690-693
116. Munger K.L., Chitnis T., and Ascherio A. Body size and risk of MS in two cohorts of US women. Neurology 73 (2009) 1543-1550
117. Zhang C., Qiu C., Hu F.B., et al. Maternal plasma 25-hydroxyvitamin D concentrations and the risk for gestational diabetes mellitus. PLoS One 3 (2008) e3753
118. Gardener H., Munger K.L., Chitnis T., Michels K.B., Spiegelman D., and Ascherio A. Prenatal and perinatal factors and risk of multiple sclerosis. Epidemiology 20 (2009) 611-618
119. Ramagopalan S.V., Dyment D.A., Ebers G.C., and Sadovnick A.D. Gestational diabetes and multiple sclerosis. Epidemiology 20 (2009) 783-784
120. Clayton D., and McKeigue P.M. Epidemiological methods for studying genes and environmental factors in complex diseases. Lancet 358 (2001) 1356-1360
121. Parra E.J. Human pigmentation variation: evolution, genetic basis, and implications for public health. Am J Phys Anthropol 134 (2007) 85-105
122. Hunter D., De Lange M., Snieder H., et al. Genetic contribution to bone metabolism, calcium excretion, and vitamin D and parathyroid hormone regulation. J Bone Miner Res 16 (2001) 371-378
123. 3 serum levels in asthma families. J Steroid Biochem Mol Biol 103 (2007) 799-802
124. Shea M.K., Benjamin E.J., Dupuis J., et al. Genetic and non-genetic correlates of vitamins K and D. Eur J Clin Nutr 63 (2009) 458-464
125. Orton S., Morris A.P., Herrera B.M., et al. Evidence for genetic regulation of vitamin D status in twins with multiple sclerosis. Am J Clin Nutr 88 (2008) 441-447
126. Snellman G., Melhus H., Gedeborg R., et al. Seasonal genetic influence on serum 25-hydroxyvitamin D levels: a twin study. PLoS One 4 (2009) e7747
127. Engelman C.D., Fingerlin T.E., Langefeld C.D., et al. Genetic and environmental determinants of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels in Hispanic and African Americans. J Clin Endocrinol Metab 93 (2008) 3381-3388
128. Lauridsen A.L., Vestergaard P., Hermann A.P., et al. Plasma concentrations of 25-hydroxy-vitamin D and 1,25-dihydroxy-vitamin D are related to the phenotype of Gc (vitamin D-binding protein): a cross-sectional study on 595 early postmenopausal women. Calcif Tissue Int 77 (2005) 15-22
129. Speeckaert M., Huang G., Delanghe J.R., and Taes Y.E. Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. Clin Chim Acta 372 (2006) 33-42
130. Kurylowicz A., Ramos-Lopez E., Bednarczuk T., and Badenhoop K. Vitamin D-binding protein (DBP) gene polymorphism is associated with Graves' disease and the vitamin D status in a Polish population study. Exp Clin Endocrinol Diabetes 114 (2006) 329-335
131. Sinotte M., Diorio C., Berube S., Pollak M., and Brisson J. Genetic polymorphisms of the vitamin D binding protein and plasma concentrations of 25-hydroxyvitamin D in premenopausal women. Am J Clin Nutr 89 (2009) 634-640
132. Ahn J., Albanes D., Berndt S.I., et al. Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk. Carcinogenesis 30 (2009) 769-776
133. Abbas S., Linseisen J., Slanger T., et al. The Gc2 allele of the vitamin D binding protein is associated with a decreased postmenopausal breast cancer risk, independent of the vitamin D status. Cancer Epidemiol Biomarkers Prev 17 (2008) 1339-1343
134. Muray S., Parisi E., Cardus A., Craver L., and Fernandez E. Influence of vitamin D receptor gene polymorphisms and 25-hydroxyvitamin D on blood pressure in apparently healthy subjects. J Hypertens 21 (2003) 2069-2075
135. Steckley J.L., Dyment D.A., Sadovnick A.D., Risch N., Hayes C., and Ebers G.C. Genetic analysis of vitamin D related genes in Canadian multiple sclerosis patients. Canadian Collaborative Study Group. Neurology 54 (2000) 729-732
136. Niino M., Kikuchi S., Fukazawa T., Yabe I., and Tashiro K. No association of vitamin D-binding protein gene polymorphisms in Japanese patients with MS. J Neuroimmunol 127 (2002) 177-179
137. Simon K.C., Munger K.L., Yang X., and Ascherio A. Polymorphisms in vitamin D metabolism related genes and risk of multiple sclerosis. Mult Scler 16 (2010) 133-138
138. Abbas S., Nieters A., Linseisen J., et al. Vitamin D receptor gene polymorphisms and haplotypes and postmenopausal breast cancer risk. Breast Cancer Res 10 (2008) R31
139. Wjst M., Altmüller J., Faus-Kessler T., Braig C., Bahnweg M., and André E. Asthma families show transmission disequilibrium of gene variants in the vitamin D metabolism and signalling pathway. Respir Res 7 (2006) 60
140. Smolders J., Damoiseaux J., Menheere P., Tervaert J.W., and Hupperts R. Association study on two vitamin D receptor gene polymorphisms and vitamin D metabolites in multiple sclerosis. Ann N Y Acad Sci 1173 (2009) 515-520
141. Smolders J., Damoiseaux J., Menheere P., Tervaert J.W., and Hupperts R. Fok-I vitamin D receptor gene polymorphism (rs10735810) and vitamin D metabolism in multiple sclerosis. J Neuroimmunol 207 (2009) 117-121
142. Ramos-Lopez E., Bruck P., Jansen T., Herwig J., and Badenhoop K. CYP2R1 (vitamin D 25-hydroxylase) gene is associated with susceptibility to type 1 diabetes and vitamin D levels in Germans. Diabetes Metab Res Rev 23 (2007) 631-636
143. Dyment D.A., Ebers G.C., and Sadovnick A.D. Genetics of multiple sclerosis. Lancet Neurol 3 (2004) 104-110
144. Ramagopalan S.V., Knight J.C., and Ebers G.C. Multiple sclerosis and the major histocompatibility complex. Curr Opin Neurol 22 (2009) 219-225
145. Ramagopalan S.V., Maugeri N.J., Handunnetthi L., et al. Expression of the multiple sclerosis-associated MHC class II allele HLA-DRB1*1501 is regulated by vitamin D. PLoS Genet 5 (2009) e1000369
146. Williams F.M., and Spector T.D. The genetics of osteoporosis. Acta Reumatol Port 32 (2007) 231-240
147. Uitterlinden A.G., Ralston S.H., Brandi M.L., et al. The association between common vitamin D receptor gene variations and osteoporosis: a participant-level meta-analysis. Ann Intern Med 145 (2006) 255-264
148. Ferrari S.L., and Rizzoli R. Gene variants for osteoporosis and their pleiotropic effects in aging. Mol Aspects Med 26 (2005) 145-167
149. Thakkinstian A., D'Este C., and Attia J. Haplotype analysis of VDR gene polymorphisms: a meta-analysis. Osteoporos Int 15 (2004) 729-734
150. Lee Y.H., Woo J.H., Choi S.J., Ji J.D., and Song G.G. Vitamin D receptor TaqI, BsmI and ApaI polymorphisms and osteoarthritis susceptibility: a meta-analysis. Joint Bone Spine 76 (2009) 156-161
151. Tajouri L., Ovcaric M., Curtain R., et al. Variation in the vitamin D receptor gene is associated with multiple sclerosis in an Australian population. J Neurogenet 19 (2005) 25-38
152. Fukazawa T., Yabe I., Kikuchi S., et al. Association of vitamin D receptor gene polymorphism with multiple sclerosis in Japanese. J Neurol Sci 166 (1999) 47-52
153. Niino M., Fukazawa T., Yabe I., Kikuchi S., Sasaki H., and Tashiro K. Vitamin D receptor gene polymorphism in multiple sclerosis and the association with HLA class II alleles. J Neurol Sci 177 (2000) 65-71
154. Partridge J.M., Weatherby S.J., Woolmore J.A., et al. Susceptibility and outcome in MS: associations with polymorphisms in pigmentation-related genes. Neurology 62 (2004) 2323-2325
155. Yeo T.W., Maranian M., Singlehurst S., Gray J., Compston A., and Sawcer S. Four single nucleotide polymorphisms from the vitamin D receptor gene in UK multiple sclerosis. J Neurol 251 (2004) 753-754
156. Dickinson J., Perera D., van der Mei A., et al. Past environmental sun exposure and risk of multiple sclerosis: a role for the Cdx-2 vitamin D receptor variant in this interaction. Mult Scler 15 (2009) 563-570
157. de Abreu D.F., Babron M.C., Rebeix I., et al. Season of birth and not vitamin D receptor promoter polymorphisms is a risk factor for multiple sclerosis. Mult Scler 15 (2009) 1146-1152
158. Australia and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene). Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat Genet 41 (2009) 824-830
159. International Multiple Sclerosis Genetics Consortium, Hafler D.A., Compston A., et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 357 (2007) 851-862
160. De Jager P.L., Jia X., Wang J., et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet 41 (2009) 776-782
161. Torkildsen O., Knappskog P.M., Nyland H.I., and Myhr K.M. Vitamin D-dependent rickets as a possible risk factor for multiple sclerosis. Arch Neurol 65 (2008) 809-811
162. Dwyer T., van der Mei I., Ponsonby A.L., et al. Melanocortin 1 receptor genotype, past environmental sun exposure, and risk of multiple sclerosis. Neurology 71 (2008) 583-589
163. Prentice A. Vitamin D deficiency: a global perspective. Nutr Rev 66 suppl 2 (2008) S153-S164
164. Hollis B.W. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr 135 (2005) 317-322
165. Heaney R.P., Davies K.M., Chen T.C., Holick M.F., and Barger-Lux M.J. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 77 (2003) 204-210
166. Baumgartl H.J., Standl E., Schmidt-Gayk H., Kolb H.J., Janka H.U., and Ziegler A.G. Changes of vitamin D3 serum concentrations at the onset of immune-mediated type 1 (insulin-dependent) diabetes mellitus. Diabetes Res 16 (1991) 145-148
167. Hypponen E., Laara E., Reunanen A., Jarvelin M.R., and Virtanen S.M. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 358 (2001) 1500-1503
168. Pozzilli P., Manfrini S., Crino A., et al. Low levels of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 in patients with newly diagnosed type 1 diabetes. Horm Metab Res 37 (2005) 680-683
169. Littorin B., Blom P., Scholin A., et al. Lower levels of plasma 25-hydroxyvitamin D among young adults at diagnosis of autoimmune type 1 diabetes compared with control subjects: results from the nationwide Diabetes Incidence Study in Sweden (DISS). Diabetologia 49 (2006) 2847-2852
170. Knekt P., Laaksonen M., Mattila C., et al. Serum vitamin D and subsequent occurrence of type 2 diabetes. Epidemiology 19 (2008) 666-671
171. Laaksi I., Ruohola J.P., Tuohimaa P., et al. An association of serum vitamin D concentrations <40 nmol/L with acute respiratory tract infection in young Finnish men. Am J Clin Nutr 86 (2007) 714-717
172. Ginde A.A., Mansbach J.M., and Camargo Jr. C.A. Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. Arch Intern Med 169 (2009) 384-390
173. Brehm J.M., Celedon J.C., Soto-Quiros M.E., et al. Serum vitamin D levels and markers of severity of childhood asthma in Costa Rica. Am J Respir Crit Care Med 179 (2009) 765-771
174. Willer C.J., Dyment D.A., Risch N.J., Sadovnick A.D., and Ebers G.C. Twin concordance and sibling recurrence rates in multiple sclerosis. Proc Natl Acad Sci USA 100 (2003) 12877-12882
175. Soilu-Hanninen M., Laaksonen M., Laitinen I., Eralinna J.P., Lilius E.M., and Mononen I. A longitudinal study of serum 25-hydroxyvitamin D and intact PTH levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis. J Neurol Neurosurg Psychiatry 79 (2008) 152-157
176. Nieves J., Cosman F., Herbert J., Shen V., and Lindsay R. High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology 44 (1994) 1687-1692
177. Smolders J., Menheere P., Kessels A., Damoiseaux J., and Hupperts R. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler 14 (2008) 1220-1224
178. Holmoy T., Moen S.M., Gundersen T.A., et al. 25-Hydroxyvitamin D in cerebrospinal fluid during relapse and remission of multiple sclerosis. Mult Scler 15 (2009) 1280-1285
179. Cree B.A., Khan O., Bourdette D., et al. Clinical characteristics of African Americans vs caucasian Americans with multiple sclerosis. Neurology 63 (2004) 2039-2045
180. Marrie R.A., Cutter G., Tyry T., Vollmer T., and Campagnolo D. Does multiple sclerosis-associated disability differ between races?. Neurology 66 (2006) 1235-1240
181. Boster A.L., Endress C.F., Hreha S.A., Caon C., Perumal J.S., and Khan O.A. Pediatric-onset multiple sclerosis in African-American black and European-origin white patients. Pediatr Neurol 40 (2009) 31-33
182. Woolmore J.A., Stone M., Pye E.M., et al. Studies of associations between disability in multiple sclerosis, skin type, gender and ultraviolet radiation. Mult Scler 13 (2007) 369-375
183. Auer D.P., Schumann E.M., Kumpfel T., Gossl C., and Trenkwalder C. Seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol 47 (2000) 276-277
184. Wuthrich R., and Rieder H.P. The seasonal incidence of multiple sclerosis in Switzerland. Eur Neurol 3 (1970) 257-264
185. Bamford C.R., Sibley W.A., and Thies C. Seasonal variation of multiple sclerosis exacerbations in Arizona. Neurology 33 (1983) 697-701
186. Embry A.F., Snowdon L.R., and Vieth R. Vitamin D and seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol 48 (2000) 271-272
187. Tremlett H., van der Mei I.A., Pittas F., et al. Monthly ambient sunlight, infections and relapse rates in multiple sclerosis. Neuroepidemiology 31 (2008) 271-279
188. Rovaris M., Comi G., Sormani M.P., Wolinsky J.S., Ladkani D., and Filippi M. Effects of seasons on magnetic resonance imaging-measured disease activity in patients with multiple sclerosis. Ann Neurol 49 (2001) 415-416
189. Killestein J., Rep M.H., Meilof J.F., et al. Seasonal variation in immune measurements and MRI markers of disease activity in MS. Neurology 58 (2002) 1077-1080
190. Andersen O., Lygner P.E., Bergstrom T., Andersson M., and Vahlne A. Viral infections trigger multiple sclerosis relapses: a prospective seroepidemiological study. J Neurol 240 (1993) 417-422
191. Panitch H.S. Influence of infection on exacerbations of multiple sclerosis. Ann Neurol 36 suppl (1994) S25-S28
192. Lund B., and Selnes A. Plasma 1,25-dihydroxyvitamin D levels in pregnancy and lactation. Acta Endocrinol (Copenh) 92 (1979) 330-335
193. Confavreux C., Hutchinson M., Hours M.M., Cortinovis-Tourniaire P., and Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in multiple sclerosis group. N Engl J Med 339 (1998) 285-291
194. Neuteboom R.F., Verbraak E., Voerman J.S., et al. Serum leptin levels during pregnancy in multiple sclerosis. Mult Scler 15 (2009) 907-912
195. Wingerchuk D.M., Lesaux J., Rice G.P., Kremenchutzky M., and Ebers G.C. A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 76 (2005) 1294-1296
196. Kimball S.M., Ursell M.R., O'Connor P., and Vieth R. Safety of vitamin D3 in adults with multiple sclerosis. Am J Clin Nutr 86 (2007) 645-651